Wellbutrin and Bezoar Formation
Wellbutrin (bupropion) can cause bezoar formation, particularly with sustained-release formulations in overdose situations, though this is a rare complication. This occurs when tablets aggregate in the gastrointestinal tract, forming a pharmacobezoar that can lead to prolonged drug absorption and potentially life-threatening toxicity.
Evidence of Bezoar Formation
The clearest evidence comes from case reports documenting pharmacobezoar formation with sustained-release bupropion:
A fatal overdose case revealed a pharmacobezoar consisting of at least 40 sustained-release bupropion tablets in the stomach, demonstrating that the medication can physically aggregate into a mass 1.
In another overdose case, bezoar formation was suspected based on altered pharmacokinetics, with a prolonged time to peak concentration (T-max of 8.25 hours) and extended half-life compared to therapeutic dosing, suggesting delayed absorption consistent with bezoar formation 2.
Clinical Context and Risk Factors
Bezoar formation with bupropion appears primarily associated with overdose situations rather than therapeutic use 1, 2. The sustained-release formulation is particularly implicated due to its tablet matrix design 1, 2.
General risk factors for medication bezoars include 3:
- Reduced gastric motility
- Loss of pyloric function
- Hypoacidity
- Presence of other predisposing gastrointestinal conditions
After bariatric surgery (particularly Roux-en-Y gastric bypass), the small gastric pouch and restricting gastro-jejunostomy create anatomical risk factors for bezoar formation 4. While these guidelines discuss bezoars in the post-bariatric surgery context, they do not specifically mention bupropion as a causative medication.
Clinical Implications
The formation of a bupropion bezoar can result in prolonged drug absorption and sustained toxic levels, as evidenced by altered pharmacokinetics in overdose cases 2. This can lead to:
- Extended duration of toxicity including seizures and CNS depression 1
- Unpredictable peak drug levels
- Prolonged need for monitoring and supportive care
Management Considerations
In suspected bupropion overdose, interventions that reduce absorption of sustained-release formulations may be effective 2. Based on general bezoar management principles 4:
- Endoscopic evaluation and potential removal for gastric bezoars
- Whole bowel irrigation may be considered
- Surgical intervention if bezoar causes obstruction in the small bowel
Important Caveats
- This complication appears rare and primarily documented in overdose scenarios 1, 2
- No evidence suggests therapeutic doses of bupropion commonly cause bezoars in patients without predisposing factors
- The FDA drug label for Wellbutrin does not list bezoar formation as a recognized adverse effect 5
- Patients with prior bariatric surgery may theoretically be at higher risk, though this specific association is not documented in the literature